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Case Report
Oral Contraceptives and Cerebral Venous Thrombosis: case report and a brief
review of literature
Mughis Sheerani, Mian Zainul Sajadeen Urfy
Department of Medicine, The Aga Khan University Hospital, Karachi.

Abstract

Case Report

Cerebral venous thrombosis remains an important
and sometimes an elusive cause of strokes. Oral contraceptives seem to have a strong causative association with this
entity. We describe a case that highlights the importance of
asking specific questions about oral contraceptive use in
patients with strokes due to cerebral venous sinus thrombosis, especially, where the cause remains cryptic.

A 42 year old house wife was admitted to the stroke
unit with sudden onset of left sided numbness and mild
weakness. She was otherwise healthy with no history of any
previous medical problems.

Introduction
The role of oral contraceptives in deep vein thrombosis has been well documented and proven in the contemporary literature. The risk of deep leg thrombosis in women
with Factor V leiden mutation who use oral contraceptives
compared with a control has been estimated to be more than
30-fold.1 Cerebral Venous sinus thrombosis represents a
rare disorder usually in middle age group. Independent trials and retrospective data analysis in several countries in the
world show markedly increased predisposition in women
who are taking oral contraceptives especially with genetic
hypercoagulable disorder.2 A recent Italian case-control
study in patients with sinus thrombosis found an odds ratio
of 4.2 for oral contraceptive use, after exclusion of pregnant
and puerperial women.3 Another study by Cerebral Venous
Sinus Study Group, Academic Medical Centre Netherlands
reported 30 fold increased risk in women who use oral contraceptives along with hereditary prothrombotic conditions
as compared to women who have neither.4
We present a case of a middle aged lady, who visited The Aga Khan University Hospital emergency department with acute neurological deficits and was later on found
to have Transverse Sinus Thrombosis. A brief review of literature is added.
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On examination her weight was 64 kg, blood pressure was 130/79 mmHg, pulse 80 per minute and she was
afebrile. General examination was unremarkable. Cardiac
and respiratory examination was also normal.
Neurological examination showed normal cranial
nerves except for mild flattening of the left naso-labial fold.
There was mild weakness on the left side which was graded as 4 on MRC scale. Left side also showed decreased sensation as compared to the right side.
Magnetic Resonance Imaging (MRI) of the brain
showed small right parietal stroke. Magnetic Resonance
Angiogram (MRA) was normal.
A workup for hypercoagulable state was performed
including anti-phospholipid antibodies, protein C & S
activity, antithrombin III, Factor V leiden deficiency and
homocystein levels were within normal range.
As no definite cause of stroke was found, the history was re-assessed. Patient was asked several directed questions about medications. It was revealed by the husband that
she had been on oral contraceptives for several days prior to
this episode. She took oral contraceptives to cease her menstrual cycle temporarily as she was going for 'Hajj'. This
information was not disclosed by the patient.
Magnetic Resonance Venogram (MRV) was performed after this information and a thrombus was seen in
the right transverse sinus.
Patient was started on anticoagulation and she recovered completely.
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Discussion
Cerebral venous sinus thrombosis is a relatively rare
condition which over the past two decades has been diagnosed more frequently due to greater availability of non
invasive diagnostic methods like MRI and MRV. It presents
usually in a relatively younger age group than other vascular neurological conditions and can result in a significant
morbidity and mortality which ranges from 5 to 30 percent.
Though relatively uncommon, CVST is a complex disease
due to multitude of etiologies that cause it. The etiologies
vary from complex hypercoaguable states to simple physiological states like dehydration, pregnancy and peurperium.5
Only a few iatrogenic factors can lead to this condition. The
oral contraceptives, androgen therapy and C-Asparaginase
therapy have been implicated as a causative factor for
CVST.
The role of oral contraceptives in the development of
deep venous sinus thrombosis is clearly established. CVST
being a rare disease, relatively scarce amount of data is
present in literature as compared to other vascular neurological abnormalities. But even with the information we have,
there is ample evidence to prove that there is a clear causal
relationship between oral contraceptives and the development of CVST. Increased incidence of CVST in oral contraceptive using women was reported for first time in 1970 by
Buchanan et al.6 Thereafter, little importance was given to
oral contraceptives as being a significant risk factor because
of lack of biological plausibility until the start of last
decade, when several retrospective studies showed a strong
causal relationship between the two. A survey from 1993-94
on health care cost and utilization in United States revealed
oral contraceptive usage as an independent risk factor for
intra-cerebral venous thrombosis.7 Since then many studies
have been published particularly from Central Europe,
establishing oral contraceptives usage as a risk factor for
CVST.8 To our knowledge, no case series or clinical trial
has been published from any center in Pakistan concerning
risk factors for CVST in our population.
In our Case Study, a complete hypercoaguable
workup was carried out and was unremarkable. The only
major risk was found to be oral contraceptives use prior to
the event. In literature, however, the use of oral contraceptives seems to be associated with CVST, more strongly in
presence of hereditary hypercoaguable disorders, like
Factor V leiden deficiency, Protein C or S and anti thrombin
deficiency and more recently prothrombin gene mutation at
position 20210 (guanine to adenine).9 This mutation was not
checked in our case as it is not available in Pakistan.
A case control study by a Dutch group on CVST
revealed that odds ratio increased from 13 to 34 in women
using oral contraceptives along with hypercoagulable disorders.4 Similar findings have been reported by 3 different
Italian Studies showing oral contraceptives alone as well in
combination with hypercoagulable disorders to be a signifi-
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cant risk factor for the development of CVST.8 This led to
the argument whether women should be screened for hypercoaguablity before prescribing oral contraceptives. The next
question was whether oral contraceptives should be withheld in women with hereditary thrombotic disorders.
Considering the prevalence of CVST which is estimated to
be around 1 per 100010, it will not be a cost effective modality and such screening is not recommended any where in the
world. As far as question of withholding oral contraceptives
in carriers of hypercoagulable genes, no clear cut guidelines
are available. It is, however, recommended that other methods of contraception should be used in women with previous episodes of thrombosis.10
As far as management of CVST is concerned, it does
not change with the attributed risk factor and includes anticoagulation with recommended guidelines. Our patient
recovered completely with anticoagulation using heparin
and then switching to warfarin as oral therapy. The prevalence of oral contraceptives use in Pakistan is relatively low
as compared to western world due to various socio-religious
reasons. Women also tend not to share this information with
their physicians, as in our case. This case also highlights the
importance of complete documentation of medication history, which may lead to diagnosis of these rare diseases and
prevent unnecessary investigations.

Conclusion
Though infrequent, CVST remains an important
cause of strokes in young individuals, with oral contraceptives as one of the iatrogenic causes. Oral contraceptives
should be prescribed with caution in women with history of
hypercoaguabilty. A detailed medications history might lead
to the diagnosis of "cryptogenic strokes" where no obvious
causes are apparent.
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